炎症性肠病母亲所生1000名儿童出生后5年内的健康结局
荷兰多中心回顾性研究纳入1999至2018年20家医院626名IBD母亲的1000名儿童,评估宫内抗TNF-α和/或硫嘌呤暴露与长期健康结局的关系。结果显示宫内暴露与抗生素治疗感染、需住院的严重感染、疫苗不良反应、生长障碍、自身免疫病及恶性肿瘤均无关联,所有结局与年龄匹配的普通人群一致。
要点
- 1000名儿童中196名(20%)宫内暴露于抗TNF-α(60名联用硫嘌呤),240名(24%)暴露于硫嘌呤单药,564名(56%)未暴露作为对照组。
- 宫内暴露于抗TNF-α和/或硫嘌呤与长期不良健康结局无关联。
- 妊娠期使用硫嘌呤者妊娠期肝内胆汁淤积症(ICP)发生率升高,但未影响出生结局及儿童长期健康结局。
核心结论
- 本研究发现宫内暴露于抗TNF-α和/或硫嘌呤与抗生素治疗感染、需住院的严重感染、疫苗不良反应、生长障碍、自身免疫病及恶性肿瘤等长期结局无关联。
研究设计与样本
- 荷兰多中心回顾性研究,纳入1999至2018年20家参与医院中分娩的IBD女性,共1000名儿童(626名母亲:381名(61%)克罗恩病、225名(36%)溃疡性结肠炎、20名(3%)未分类IBD)。
- 从母亲及病历中获取疾病特征、用药、生活方式、妊娠结局及儿童长期健康结局信息,经父母双方同意后从全科医生处收集至5岁的结局。
- 主要目标为评估感染率,次要目标为评估疫苗不良反应、生长、自身免疫病及恶性肿瘤。
主要发现
- 196名(20%)儿童宫内暴露于抗TNF-α(其中60名联用硫嘌呤),240名(24%)暴露于硫嘌呤单药,564名(56%)未暴露于抗TNF-α和/或硫嘌呤作为对照组。
- 宫内暴露于IBD治疗与不良长期健康结局之间无关联。
- 妊娠期使用硫嘌呤者妊娠期肝内胆汁淤积症(ICP)发生率升高,但未影响出生结局及儿童长期健康结局。
- 所有结局与年龄匹配的普通人群一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes. DESIGN: We performed a multicentre retrospective study in The Netherlands. Women with IBD who gave birth between 1999 and 2018 were enrolled from 20 participating hospitals. Information regarding disease characteristics, medication use, lifestyle, pregnancy outcomes and long-term health outcomes of children was retrieved from mothers and medical charts. After consent of both parents, outcomes until 5 years were also collected from general practitioners. Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies. RESULTS: We included 1000 children born to 626 mothers (381 (61%) Crohn's disease, 225 (36%) ulcerative colitis and 20 (3%) IBD unclassified). In total, 196 (20%) had intrauterine exposure to anti-tumour necrosis factor-α (anti-TNF-α) (60 with concomitant thiopurine) and 240 (24%) were exposed to thiopurine monotherapy. The 564 children (56%) not exposed to anti-TNF-α and/or thiopurine served as control group. There was no association between adverse long-term health outcomes and in utero exposure to IBD treatment. We did find an increased rate of intrahepatic cholestasis of pregnancy (ICP) in case thiopurine was used during the pregnancy without affecting birth outcomes and long-term health outcomes of children. All outcomes correspond with the general age-adjusted population. CONCLUSION: In our study, we found no association between in utero exposure to anti-TNF-α and/or thiopurine and the long-term outcomes antibiotic-treated infections, severe infections needing hospital admission, adverse reactions to vaccinations, growth failure, autoimmune diseases and malignancies.
引用
- Kanis SL, Modderman S, Escher JC, et al. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut. 2020. PMID: 33046558. doi:10.1136/gutjnl-2019-319129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。